Literature DB >> 22452358

A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project.

Silvia Ravera1, Susana P Monteiro, Johan Jacob de Gier, Trudy van der Linden, Trinidad Gómez-Talegón, F Javier Alvarez.   

Abstract

AIMS: To illustrate (i) the criteria and the development of the DRUID categorization system, (ii) the number of medicines that have currently been categorized, (iii) the added value of the DRUID categorization system and (iv) the next steps in the implementation of the DRUID system.
METHODS: The development of the DRUID categorization system was based on several criteria. The following steps were considered: (i) conditions of use of the medicine, (ii) pharmacodynamic and pharmacokinetic data, (iii) pharmacovigilance data, including prevalence of undesirable effects, (iv) experimental and epidemiological data, (v) additional data derived from the patient information leaflet, existing categorization systems and (vi) final categorization. DRUID proposed four tiered categories for medicines and driving.
RESULTS: In total, 3054 medicines were reviewed and over 1541 medicines were categorized (the rest were no longer on the EU market). Nearly half of the 1541 medicines were categorized 0 (no or negligible influence on fitness to drive), about 26% were placed in category I (minor influence on fitness to drive) and 17% were categorized as II or III (moderate or severe influence on fitness to drive).
CONCLUSIONS: The current DRUID categorization system established and defined standardized and harmonized criteria to categorize commonly used medications, based on their influence on fitness to drive. Further efforts are needed to implement the DRUID categorization system at a European level and further activities should be undertaken in order to reinforce the awareness of health care professionals and patients on the effects of medicines on fitness to drive.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22452358      PMCID: PMC3522805          DOI: 10.1111/j.1365-2125.2012.04279.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Can patients taking opioids drive safely? A structured evidence-based review.

Authors:  David A Fishbain; R B Cutler; H L Rosomoff; R Steele Rosomoff
Journal:  J Pain Palliat Care Pharmacother       Date:  2002

Review 2.  Medicinal drugs and driving: from research to clinical practice.

Authors:  F Javier Alvarez; M Carmen del Río
Journal:  Trends Pharmacol Sci       Date:  2002-09       Impact factor: 14.819

Review 3.  A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions.

Authors:  Erin Kelly; Shane Darke; Joanne Ross
Journal:  Drug Alcohol Rev       Date:  2004-09

4.  [Intravitreal injections: AFSSAPS guide to good practice].

Authors:  B Bodaghi; J F Korobelnik; I Cochereau; J Hajjar; F Goebel; N Dumarcet
Journal:  J Fr Ophtalmol       Date:  2012-01-05       Impact factor: 0.818

Review 5.  Which older patients are competent to drive? Approaches to office-based assessment.

Authors:  David B Hogan
Journal:  Can Fam Physician       Date:  2005-03       Impact factor: 3.275

6.  Drugs and driving.

Authors:  F J Alvarez; M C del Rio
Journal:  Lancet       Date:  1994-07-30       Impact factor: 79.321

7.  Drugs and alcohol among suspected impaired drivers in Canton de Vaud (Switzerland).

Authors:  M Augsburger; L Rivier
Journal:  Forensic Sci Int       Date:  1997-02-28       Impact factor: 2.395

  7 in total
  17 in total

1.  Receipt of Warnings Regarding Potentially Impairing Prescription Medications and Associated Risk Perceptions in a National Sample of U.S. Drivers.

Authors:  Robin A Pollini; Geetha Waehrer; Tara Kelley-Baker
Journal:  J Stud Alcohol Drugs       Date:  2017-11       Impact factor: 2.582

2.  Validity and reliability of a driving simulator for evaluating the influence of medicinal drugs on driving performance.

Authors:  Mari Iwata; Kunihiro Iwamoto; Iwao Kitajima; Takasuke Nogi; Koichi Onishi; Yu Kajiyama; Izumi Nishino; Masahiko Ando; Norio Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2020-11-24       Impact factor: 4.530

3.  Medicines and driving: evaluation of training and software support for patient counselling by pharmacists.

Authors:  Sara-Ann Legrand; Sofie Boets; Uta Meesmann; Alain G Verstraete
Journal:  Int J Clin Pharm       Date:  2012-06-08

4.  Road traffic crash risk associated with benzodiazepine and z-hypnotic use after implementation of a colour-graded pictogram: a responsibility study.

Authors:  Ludivine Orriols; Audrey Luxcey; Benjamin Contrand; Blandine Gadegbeku; Bernard Delorme; Aurore Tricotel; Nicholas Moore; Louis-Rachid Salmi; Emmanuel Lagarde
Journal:  Br J Clin Pharmacol       Date:  2016-09-09       Impact factor: 4.335

5.  A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines.

Authors:  Bas Emich; Liset van Dijk; Susana P Monteiro; Johan J de Gier
Journal:  Int J Clin Pharm       Date:  2014-09-10

6.  Use of driving-impairing medicines by a Spanish population: a population-based registry study.

Authors:  Eduardo Gutierrez-Abejón; Francisco Herrera-Gómez; Paloma Criado-Espegel; F Javier Alvarez
Journal:  BMJ Open       Date:  2017-11-22       Impact factor: 2.692

7.  Roadside opioid testing of drivers using oral fluid: the case of a country with a zero tolerance law, Spain.

Authors:  Inmaculada Fierro; Mónica Colás; Juan Carlos González-Luque; F Javier Álvarez
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-05-10

8.  Driving and legal status of Spanish opioid-dependent patients.

Authors:  Carlos Roncero; F Javier Álvarez; Carmen Barral; Susana Gómez-Baeza; Begoña Gonzalvo; Laia Rodríguez-Cintas; M Teresa Brugal; Carlos Jacas; Anna Romaguera; Miguel Casas
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-06-03

Review 9.  Assessment of cognitive safety in clinical drug development.

Authors:  Jonathan P Roiser; Pradeep J Nathan; Adrian P Mander; Gabriel Adusei; Kenton H Zavitz; Andrew D Blackwell
Journal:  Drug Discov Today       Date:  2015-11-22       Impact factor: 7.851

10.  The Problem of Benzodiazepine Use and Its Extent in the Driver Population: A Population-Based Registry Study.

Authors:  Francisco Herrera-Gómez; Eduardo Gutierrez-Abejón; Paloma Criado-Espegel; F Javier Álvarez
Journal:  Front Pharmacol       Date:  2018-04-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.